BerGenBio
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
BerGenBio is a clinical-stage biopharmaceutical company that develops innovative drugs for aggressive diseases. The company's primary focus is on its pipeline of first-in-class selective AXL kinase inhibitors, with its lead candidate being bemcentinib. These inhibitors are designed to treat conditions such as cancer and severe respiratory infections by targeting AXL, a key mediator of drug resistance, immune evasion, and metastasis. In June 2025, the company announced a proposed merger with Oncoinvent, an innovator in radiopharmaceutical cancer therapies, to expand its oncology pipeline and therapeutic capabilities.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-28 10:42 |
Prospectus
BerGenBio ASA: Approval and publication of prospectus
|
English | 9.9 KB | ||
| 2025-10-24 08:00 |
M&A Activity
BerGenBio and Oncoinvent - Key Dates for Completion of Merger
|
English | 9.4 KB | ||
| 2025-09-17 08:56 |
Share Issue/Capital Change
BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue
|
English | 10.0 KB | ||
| 2025-09-17 08:55 |
Share Issue/Capital Change
BerGenBio ASA: Updated information regarding the contemplated Rights Issue and …
|
English | 3.6 KB | ||
| 2025-08-20 07:00 |
Interim Report
BerGenBio First half results 2025 - Attachment: H1_2025_Financial_report.pdf
|
English | 905.6 KB | ||
| 2025-08-20 07:00 |
Earnings Release
BerGenBio First half results 2025
|
English | 5.4 KB | ||
| 2025-08-05 16:49 |
Share Issue/Capital Change
BerGenBio ASA - Updated key information related to the rights issue
|
English | 10.0 KB | ||
| 2025-08-04 13:40 |
Post-Annual General Meeting Information
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
Norwegian | 794.1 KB | ||
| 2025-08-04 13:40 |
M&A Activity
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
English | 2.2 KB | ||
| 2025-07-03 14:53 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting - Attachment: BerGenBio_…
|
Norwegian | 441.1 KB | ||
| 2025-07-03 14:53 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting
|
English | 2.6 KB | ||
| 2025-06-30 22:30 |
Share Issue/Capital Change
BerGenBio ASA - Key information related to the rights issue
|
English | 10.0 KB | ||
| 2025-06-30 22:05 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
|
English | 101.2 KB | ||
| 2025-06-30 22:05 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue
|
English | 21.0 KB | ||
| 2025-06-30 22:00 |
M&A Activity
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
|
English | 19.5 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
